Clinical Trials Logo

Leukopenia clinical trials

View clinical trials related to Leukopenia.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT06276036 Active, not recruiting - Cytopenia Clinical Trials

Autoimmune Cytopenias as a Sign of Primary Immunodeficiency.

Start date: July 23, 2019
Phase: N/A
Study type: Interventional

Autoimmune cytopenias resistant to treatment are among the most common clinical manifestations observed in patients with congenital alterations of the immune system, such as primary immunodeficiencies (PI). The exact contribution of immune system alterations to the pathogenesis of autoimmune cytopenias has not yet been fully elucidated. Moreover, conventionally employed therapeutic strategies often fail, leading to increased healthcare costs, high morbidity, and even mortality. Therefore, there is a need to establish clinical guidelines for diagnosis and to identify early biomarkers capable of identifying individuals responsive to therapy. Thus, a systematic approach to the study of such pathologies will allow for the identification of early biomarkers and facilitate the development of targeted therapeutic strategies

NCT ID: NCT04283695 Active, not recruiting - Leukopenia Clinical Trials

To Investigate the Absorption, Metabolism, Excretion, Absolute Bioavailability, and Immunogenicity of GX-I7 in Healthy Volunteers

Start date: July 3, 2019
Phase: Early Phase 1
Study type: Interventional

A Phase 1, open-labeled, single-dose, one-sequence, one-period, 3-part study to investigate the absorption, metabolism, excretion, absolute bioavailability, and immunogenicity of GX-I7 in healthy volunteers

NCT ID: NCT03469895 Active, not recruiting - Clinical trials for Autoimmune Cytopenia Associated With Chronic Lymphocytic Leukemia

Autoimmune Cytopenia and BcR Inhibitors

CABRI
Start date: July 21, 2017
Phase:
Study type: Observational

Efficacy of BCR Inhibitors in the Treatment of Autoimmune Cytopenias Associated with Chronic Lymphocytic Leukemia (CLL): A Retrospective Analysis of the French Innovative Leukemia Organization (FILO)

NCT ID: NCT02566304 Active, not recruiting - Clinical trials for Acute Myeloid Leukemia

Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Start date: November 13, 2015
Phase: Phase 2
Study type: Interventional

This clinical trial studies the use of reduced intensity chemotherapy and radiation therapy before donor stem cell transplant in treating patients with hematologic malignancies. Giving low doses of chemotherapy, such as cyclophosphamide and fludarabine phosphate, before a donor stem cell transplant may help stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Reducing the intensity of the chemotherapy and radiation may also reduce the side effects of the donor stem cell transplant.